Vudalimab is a potent dual CTLA-4 and promotes tumor-selective T-cell activation[1].
XmAb20717 has binding avidity and contributes to T cell activation, including IL-2, CD45+ cells, and IFNγ[1].
XmAb20717 (every two days, for 16 d; NSG mice engrafted with KG1a-luc followed by engraftment with huPBMCs) enhances allogeneic anti-tumor responses in mice[1].
[1]. Hedvat M, et, al. Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T Cell Activation and Proliferation.